Dutch Researchers Make Breakthrough That Could Pave the Way to a Cure for Type 1 Diabetes
In a significant medical advance, researchers in the Netherlands have achieved a breakthrough that could radically change the future for people living with type 1 diabetes. For the first time, scientists at Leiden University Medical Center have successfully used lab-grown insulin-producing islet cells to restore natural insulin production in patients. This innovation signals a new era of hope—one where type 1 diabetes may become a manageable, or even curable, disease.
Understanding Type 1 Diabetes: The Unmet Challenge
Type 1 diabetes is a chronic, life-altering autoimmune disease that usually develops in childhood or adolescence, but can occur at any age. The body’s immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. Without insulin, a hormone that regulates blood sugar, glucose builds up in the blood, leading to serious complications—heart disease, kidney failure, blindness, nerve damage, and more. Daily insulin injections, careful diet management, and constant blood sugar monitoring become a way of life for those affected.
Despite advances in insulin therapies and diabetes technology, there has been no cure. The ultimate goal in diabetes research has been to find a way to restore the body’s own ability to produce insulin, thereby freeing patients from constant management and the risk of severe complications.
The Breakthrough: Lab-Grown Islet Cells Restore Insulin Production
Researchers at Leiden University Medical Center have taken a significant step toward this goal. In a recent clinical trial, a small group of people with severe type 1 diabetes received infusions of islet cells—tiny clusters of insulin-producing cells—created from pluripotent stem cells in the laboratory.
What sets this apart?
Traditionally, islet cell transplantation has relied on donor organs, a process hampered by severe shortages and the need for lifelong immunosuppressant medication to prevent rejection. The Dutch team’s innovation bypasses these obstacles. By growing islet cells from pluripotent stem cells, scientists have created an unlimited, renewable source of insulin-producing cells. This method not only addresses the donor shortage, but also opens up the possibility of personalized treatments using a patient’s own cells in the future.
Early results have been striking. Most trial participants were able to produce their own insulin and maintain stable blood sugar levels without external injections for at least a year after receiving the infusion. For these patients, it was the first time since diagnosis that their own bodies were capable of regulating glucose naturally.
How the Process Works: From Stem Cell to Pancreatic Islet
- Stem Cell Harvesting: Pluripotent stem cells, which have the ability to develop into any type of cell, are cultivated in the laboratory.
- Cell Differentiation: Using precise biochemical cues, scientists guide these stem cells to develop into pancreatic islet cells, specifically the beta cells responsible for insulin production.
- Transplantation: The lab-grown islet cells are then transplanted into the patient, typically into the liver or the peritoneal cavity, where they integrate and begin producing insulin in response to the body’s needs.
- Immunosuppression: Currently, recipients must take medications to prevent immune rejection of the new cells—a major challenge the team is working to overcome.
Addressing the Major Hurdles: Immune Suppression and Long-Term Safety
While the results are promising, the journey to a widely available cure is not without challenges. The need for lifelong immunosuppression remains a significant concern. Immunosuppressants can leave patients vulnerable to infections and other side effects. The Leiden team and other global research groups are working to develop ways to “train” the immune system to accept transplanted cells, or to create “immune cloaks” that shield transplanted cells from attack.
Additionally, long-term studies are required to confirm that the transplanted cells remain viable and effective over many years, and that there are no unforeseen complications. As with any new therapy, rigorous testing and regulatory approval are essential steps before widespread adoption.
The Next Steps: Cure One Center and the Future of Diabetes Treatment
To accelerate research and bring these therapies to more people, a dedicated research and treatment center, Cure One, will open in Leiden in November 2025. The center’s mission is to lead the world in stem cell and immune-adaptation therapies for diabetes. Cure One aims to expand clinical trials, refine transplantation techniques, and develop ways to personalize islet cell therapies, potentially using a patient’s own stem cells to eliminate immune rejection.
Cure One will also collaborate with international partners exploring similar avenues, such as 3D-printed islet cells and advanced gene-editing technologies. Researchers recently demonstrated that 3D-printed human islet cells, created with bio-ink from real pancreatic tissue, remain functional in the lab for weeks and show promise in animal models. This could further reduce barriers to treatment access, paving the way for “off-the-shelf” cell therapies.
A Transformative Moment for Diabetes Research
This breakthrough marks a turning point. For decades, the idea of curing type 1 diabetes has seemed out of reach—a distant dream for millions worldwide. Now, the prospect of functional cures, based on regenerative medicine, is within sight.
For patients, this means:
- The real possibility of life without constant insulin injections or pumps.
- Freedom from the fear of sudden blood sugar crashes or long-term complications.
- Hope for children diagnosed today, who may grow up with far better treatment options—or even cures.
However, researchers and clinicians urge caution. Widespread use of lab-grown islet cell transplants will require further validation, expanded clinical trials, and solutions for immune rejection. Still, the field is evolving rapidly. The combination of stem cell technology, advanced cell manufacturing, and immune engineering could soon turn the dream of a diabetes cure into a reality.
The Road Ahead
As of mid-2025, several milestones are in sight:
- November 2025: Opening of the Cure One center in Leiden.
- 2025–2028: Larger clinical trials to confirm safety and effectiveness.
- Ongoing: Refinement of immune-protective strategies and movement toward personalized therapies.
If successful, these therapies could transform the lives of millions living with type 1 diabetes, while also offering hope for people with type 2 diabetes and other endocrine disorders. The Netherlands is now at the forefront of this global medical revolution—bringing new optimism to the diabetes community and setting the stage for what may become one of the greatest achievements in modern medicine.
About The Author
